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Aim
To evaluate safety and efficacy in young adults with JIA
treated by TNF and non anti-TNF inhibitors.
Methods
36 patients (F26-M10, median age 18,8 yrs) with JIA treated
with anti-TNF (17 etanercept, 4 infliximab, 15 adalimumab)
followed at Transition Clinic of Florence from January 2008
to December 2010 were enrolled in a observational, single-
centre, retrospective study. 12 pts (4 etanercept, 4 inflixi-
mab, 4 adalimumab) failed to respond or did not tolerate
the first therapy and switched to a second one. Moreover,
9 patients has received non anti-TNF drug (5 abatacept,
4 tocilizumab). In all, 53 treatments (19 etanercept, 5 inflix-
imab, 20 adalimumab, 5 abatacept, 4 tocilizumab) were per-
formed. Safety assessments were based on adverse events
(AEs) report, divided in moderate AES (if infective events
or injection site reactions have been occurred) and severe
AES (including infusion reactions). Efficacy was assessed
using the PedACR30/50/70 criteria.
Results
Of the 36 patients treated with TNF-blockers, Ped
ACR30/50/70 response was reached by 78%/67%/58%
after 24 weeks, 72%/68%/60% after 48 weeks and 87%/
87%/73% after 96 weeks of treatment. Of the 9 patients
treated with abatacept or tocilizumab, PedACR30/50/70
response was reached by 89%/78%/67% after 24 weeks,
80%/80%/80% after 48 weeks and 75%/75%/75% after
96 weeks. 108 AEs (both moderate and serious)
occurred in 26 patients (59%) treated with anti-TNF.
Among non anti-TNF agents, 36 AEs occurred in
7 patients (78%), no one was serious and any patient
leaved the biological treatment due to AEs.
Conclusions
In our study, anti-TNF agents were well tolerated and
provided clinically significant efficacy in young adults
with JIA. In the refractory systemic form of JIA, tocilizu-
mab seemed to be effective and safe.
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